Member Info for Sangijuelas1

Because the vast majority of UK investors don't have a clue about RPA and intelligent automation.

And now looks like in auction

.

Tinners if you were not here to just talk down the price you would do as I suggest and compare the 4D investment spend with that of its US peers such as Evelo Biosciences and Seres Therapeutics.

They are doing much less with 2-3 times the expenditure

A reminder of the PATH market cap vs BP

$35bn

More for me at 835

II background selling. Probably the cucks at Jupiter.
They sold Angle down to 40p earlier in the year and it's now at 120p.

I met one of their fund managers once. Couldn't manage his dandruff as he was covered in it so how he could manage a portfolio I don't know.

They are still trying to recoup their losses from shorting Tesla a couple of years ago

Still getting great customer reviews on Gartner
https://www.gartner.com/reviews/market/robotic-process-automation-software/vendor/blue-prism/product/blue-prism

The more they drop it the more I am buying

Bought in here as well at this ridiculous price. Had been holding off as clearly been a seller.

See you at £15

I left it too late. No issues with the data requested as no doubt it is a legal and practical requirement.

NI number, address and dealing account details.

In what way have I been deramping?

I posted stuff on Stocktwits yesterday that was upbeat.

I pointed out on here, in response to someone saying that 0518 data was due this month, that the last update said it might not be until the autumn.

Looking to keep this as long term hold. And collect the growing dividends.

It doesn't have to be all or nothing. You can just trade the margins and keep a core.

Only way to treat baby bios

Lives

Xenor potential short term rebalance in the hope of gains elsewhere, against the probability of money sitting idle here for a couple of months

I was going by memory Phil and when it was said while watching the presentation I took it to mean much later than the original forecast given of June, which was why I was so overweight here.

The Blautix data released recently was originally due at the end of last year.

These are my interpretations and you are entitled to make your own.

Last week there was plenty of talk of June and that was one of the factors driving the recent rise.

Big investment houses speak to companies as part of a larger due diligence process. It's good to have the opportunity to speak with them but they are unlikely to start investing 5 minutes after having a conversation.

PATH is the future of office work . I ended up investing in them after doing a lot of research into Blue Prism, which was heavily discounted but all I kept finding was that PATH were so incredibly far ahead that the fact they are worth 40x what Prism are there are good reasons for that.

I did buy a load more 4D on the drop into the 90s so I was well overweight.
Saying that after the Blautix drop last year I had the whole of my ISA in 4D at one point

When a little pharma co says into Autumn they mean into Autumn.

That doesn't mean that there wouldn't be other developments.

I was also in the process of rebalancing my portfolio as overexposed to biotech companies and needing to explore some other opportunities like PATH and AFRM

Yeah I trimmed about 20% at 108 as very overweight here and don't want money sitting idle through the next couple of months.

Once traders expecting June news have moved on no doubt I will be able to buy back in the 90s